Melanoma, the most dangerous form of skin cancer, often hides in plain sight. While many are vigilant about obvious changes ...

Survival rates are estimates based on ... depending on a person’s race, gender, and age. The American Academy of Dermatology states that melanoma develops more often on the legs in females ...

A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for ...

The team calculated incidence rates and survival outcomes by age, sex, and year of diagnosis. Patricia Pedregal-Pascual, joint first author and clinician specializing in gastroenterology from ...

Study findings suggested that assessing ctDNA levels was as good or better at predicting recurrence than experimental tests ...

immunotherapy is active in malignant melanoma, and clinical trial data suggest that combined chemotherapy and immunotherapy (i.e. biochemotherapy) increases response rates; however, the results of ...

The burden of low-grade toxicity is clinically significant in patients treated with adjuvant pembrolizumab for stage III melanoma.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...